Peking University People's Hospital

Other

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

308

Clinical Trials↗

All sponsored trials (all statuses)

Pipeline

Pipeline Snapshot

By Phase

20 drugs in development

Phase 33

Phase 211

Phase 12

Preclinical6

By Therapeutic Area

top 6

Oncology

938%

Hematology

28%

Metabolic & Endocrine

14%

Nephrology

14%

Infectious Disease

14%

Immunology

14%

R&D Momentum

91/100

Pipeline Velocity

71/100

Trial Completion Rate

79/100

Pipeline Concentration

30/100

Pipeline Freshness

57/100

Strategic Signals

↗Active in Metabolic & Endocrine but thin pipeline — potential licensing opportunity

Activity

Recent Activity

Last 14 days

Oct 30, 2026

Recruiting

Hemophagocytic Lymphohistiocytosis After Hematopoietic Stem Cell Transplantation: A Multicenter Ambispective Longitudinal Cohort Study

Oct 27, 2026

Recruiting

Establishment of Post-Operative Optimal Surveillance Model and Adaptive Treatment Decision System Based on MRD Molecular Response Combined With Pathological Response Status

Earlier

Oct 22, 2026TrialctDNA-MRD and Imaging Response-Guided Adaptive Escalation of Neoadjuvant Therapy in Resectable and Borderline Resectable Non-Small Cell Lung Cancer: A Single-Arm, Proof-of-Concept Study

Oct 17, 2026TrialA Clinical Study of Weight Management-Induced AMPK Activation as an Adjunctive Treatment for Endometrial Cancer

Oct 17, 2026TrialCirculating Tumor DNA Testing in Patients With Large B-Cell Lymphoma: A Prospective Study

Oct 15, 2026TrialctDNA-MRD-Guided Aumolertinib-Based Adjuvant Therapy for Resected EGFR-Mutant Non-Small Cell Lung Cancer: A Real-World Interventional Study

Oct 10, 2026TrialA Prospective, Single-Center, Randomized Controlled Clinical Study on N-Acetyl-L-Cysteine Promoting Hematopoietic Recovery in Patients With Newly Diagnosed Low/Intermediate-Risk Acute Myeloid Leukemia After Complete Remission

Oct 8, 2026TrialVideo-Assisted Ablation of Pilonidal Sinus (VAAPS) Combined With Loose Seton Drainage for Postoperative Self-Care: A Prospective Single-Arm Cohort Study

4 more events

Oct 6, 2026TrialA Prospective, Single-Arm Study of Laparoscopic and Endoscopic Cooperative Surgery (LECS) Combined With Laparoscopic Sentinel Node Navigation Surgery (LSNNS) for Early Gastric Cancer (LENS Trial)

Oct 3, 2026TrialA Prospective, Single-Arm Study of Anti-HER2 Antibody-Drug Conjugates in HER2-Positive Homogeneous and Heterogeneous Early Breast Cancer as Neoadjuvant Therapy

Oct 1, 2026TrialStudy on the Efficacy and Safety of Initial Combination of Finerenone and Semaglutide in Non-diabetic Adult Patients With Obesity Complicated by Chronic Kidney Disease With Albuminuria

Sep 29, 2026TrialSwitching to A1811 vs. Continuation of the Original Neoadjuvant Regimen After THP Induction in HER2-Positive Breast Cancer

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Pipeline

Drug Pipeline

Therapeutic Area

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Hematology(2 drugs)

—

Hematology(2 drugs)

Immunology(1 drug)

—

Immunology(1 drug)

Infectious Disease(1 drug)

—

Infectious Disease(1 drug)

Metabolic & Endocrine(1 drug)

—

Metabolic & Endocrine(1 drug)

Nephrology(1 drug)

—

Nephrology(1 drug)

Oncology(9 drugs)

—

Oncology(9 drugs)

Unknown / Other(9 drugs)

—

Unknown / Other(9 drugs)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)